1. Home
  2. AVTX vs FCO Comparison

AVTX vs FCO Comparison

Compare AVTX & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • FCO
  • Stock Information
  • Founded
  • AVTX 2011
  • FCO 1991
  • Country
  • AVTX United States
  • FCO United Kingdom
  • Employees
  • AVTX N/A
  • FCO N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • FCO Investment Managers
  • Sector
  • AVTX Health Care
  • FCO Finance
  • Exchange
  • AVTX Nasdaq
  • FCO Nasdaq
  • Market Cap
  • AVTX 88.4M
  • FCO 80.3M
  • IPO Year
  • AVTX 2015
  • FCO N/A
  • Fundamental
  • Price
  • AVTX $7.35
  • FCO $5.97
  • Analyst Decision
  • AVTX Strong Buy
  • FCO
  • Analyst Count
  • AVTX 4
  • FCO 0
  • Target Price
  • AVTX $33.00
  • FCO N/A
  • AVG Volume (30 Days)
  • AVTX 54.4K
  • FCO 100.1K
  • Earning Date
  • AVTX 03-28-2025
  • FCO 01-01-0001
  • Dividend Yield
  • AVTX N/A
  • FCO 14.96%
  • EPS Growth
  • AVTX N/A
  • FCO N/A
  • EPS
  • AVTX N/A
  • FCO 0.43
  • Revenue
  • AVTX $820,000.00
  • FCO N/A
  • Revenue This Year
  • AVTX N/A
  • FCO N/A
  • Revenue Next Year
  • AVTX N/A
  • FCO N/A
  • P/E Ratio
  • AVTX N/A
  • FCO $12.30
  • Revenue Growth
  • AVTX N/A
  • FCO N/A
  • 52 Week Low
  • AVTX $4.18
  • FCO $4.73
  • 52 Week High
  • AVTX $34.46
  • FCO $6.63
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 42.79
  • FCO 46.09
  • Support Level
  • AVTX $7.42
  • FCO $5.92
  • Resistance Level
  • AVTX $8.50
  • FCO $6.13
  • Average True Range (ATR)
  • AVTX 0.64
  • FCO 0.11
  • MACD
  • AVTX 0.02
  • FCO -0.02
  • Stochastic Oscillator
  • AVTX 17.16
  • FCO 14.29

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About FCO abrdn Global Income Fund Inc.

abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.

Share on Social Networks: